Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys

Menopause

Volumn 14, Issue 1, 2007, Pages 97-105

  Lees, Cynthia ^a,b   Shen, Victor ^a   Brommage, Robert ^a  

^a Department of Pathology   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bone biomarkers; Bone mass; Bone strength; Lasofoxifene; Monkeys

Indexed keywords

ALKALINE PHOSPHATASE; CONJUGATED ESTROGEN; ESTRADIOL; LASOFOXIFENE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR; FOLLOW UP; HIP; ILIAC BONE; LUMBAR VERTEBRA; MONKEY; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BODY WEIGHT; BONE DENSITY; COLLAGEN TYPE I; ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); MACACA FASCICULARIS; OSTEOPOROSIS; OVARIECTOMY; PEPTIDES; POSTMENOPAUSE; PYRROLIDINES; SPINE; TETRAHYDRONAPHTHALENES;

EID: 33846110438     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000227858.50473.69     Document Type: Article

References (18)

1. The Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
3. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocrine Rev 1999;20:418-434.
4. Delmas P. Clinical use of selective estrogen receptor modulators. Bone 1999;25:115-118.
5. Bolognese MA, Weiss SR, Ettinger MP, Moffett AH, Lee A. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) for the prevention of bone loss in postmenopausal women. Osteoporos Int 2004;15(Suppl 1):S11.
6. Clung M, Omizo M, Weiss S, et al. Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. ASBMR 2004 [abstract]. Presented at: 26th Annual Meeting of the American Society for Bone and Mineral Research; October 1-5, 2004; Seattle, WA.
7. Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 2002;9:320-328.
8. Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005;8:13-23.
9. Hotchkiss CE. Use of peripheral quantitative computed tomography for densitometry of the femoral neck and spine in cynomolgus monkeys (Macaca fascicularis). Bone 1999;24:101-107.
10. Goodwin BT, Jerome CP. Iliac biopsy for histomorphometric analysis of trabecular bone in cynomolgus monkeys and baboons. Lab Anim Sci 1987;37:213-216.
11. Erben RG. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 1997;45:307-313.
12. Brommage R, Vafai H. Rapid embedding protocol for visualizing bone mineral and matrix. Calcif Tissue Int 2000;67:479.
13. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
14. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 1998;139:2068-2076.
15. Ke HZ, Folley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005.
16. Brommage R. Perspectives on using nonhuman primates to understand the etiology and treatment of postmenopausal osteoporosis. J Musculoskel Neuron Interact 2001;1:307-325.
17. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-2586.
18. McClung M, Portman D, Emkey R, et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene [abstract]. Presented at: 26th Annual Meeting of the American Society for Bone and Mineral Research; October 1-5, 2004; Seattle, WA.